Clinical TrialID 2210

Beta-cryptoxanthin Supplement: Absorption and Function

NCT05046457

Beta-cryptoxanthin Supplementation

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
2210
Evidence Id
2210
Core Evidence Id
2210
Source Clinical Trial Id
2184
Herb2 Clinical Trial Id
HBCT002184
Nct Id
NCT05046457
Title
Beta-cryptoxanthin Supplement: Absorption and Function
Status
Completed
Phase
Study Result
No
Study Condition
Beta-cryptoxanthin Supplementation
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
Intervention
DIETARY_SUPPLEMENT: Beta-cryptoxanthin (BCX)
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Triple
Intervention Purpose
Basic_Science
Gender
Female
Age
Adult
Enrollment
90
Outcome Measure
Change in plasma concentration of BCX over 8 weeks, Fasting plasma carotenoids concentrations, Baseline, Week 2, Week 4, Week 8
Sponsor Collaborator
Institute for Human Development and Potential (IHDP), Singapore|DSM Nutritional Products, Inc.
Funded By
OTHER
Location
Singapore Institute for Clinical Sciences, Singapore, Singapore
Other Id
2021/00455
Start Date
2021-09-07
Primary Completion Date
2022-03-31
Completion Date
2022-03-31
First Posted
2021-09-16
Results First Posted
Last Update Posted
2022-04-13
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05046457
Title Cn
Title En
Beta-cryptoxanthin Supplement: Absorption and Function
Bilingual Status
semi_complete